Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kiniksa Pharmaceuticals InternationalKNSA +0.83%46 3-Year EBITDA Growth Rate is 79.30% as of Jun. 2026, which is 217% above its 10-year median of 25.00. GuruFocus rates KNSA with a GF Score™ of 46/100 and a GF Value™ of $55.28 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 809 Drug Manufacturers companies, Kiniksa Pharmaceuticals International ranks better than 95.67% on this metric.
During the past 12 months, Kiniksa Pharmaceuticals International's average EBITDA Per Share Growth Rate was 2294.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 79.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Kiniksa Pharmaceuticals International was 79.30% per year. The lowest was -61.40% per year. And the median was 25.00% per year.
Kiniksa Pharmaceuticals International (NAS:KNSA) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Kiniksa Pharmaceuticals International 3-Year EBITDA Growth Rate Related Terms
KNSA vs AMRX, LQDA, LNTH: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiniksa Pharmaceuticals International 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Kiniksa Pharmaceuticals International's 3-Year EBITDA Growth Rate falls into.
Kiniksa Pharmaceuticals International 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 79.30% mean?
Kiniksa Pharmaceuticals International (KNSA) has a 3-Year EBITDA Growth Rate of 79.30% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Kiniksa Pharmaceuticals International and its competitors. This is 217% above median its historical median of 25.00. According to the industry distribution chart, Kiniksa Pharmaceuticals International ranks #35 out of 809 companies in the Drug Manufacturers industry, placing it in the top 4.3%.
Is Kiniksa Pharmaceuticals International's 3-Year EBITDA Growth Rate too high?
Kiniksa Pharmaceuticals International's current 3-Year EBITDA Growth Rate of 79.30% is 217% above median its 10-year median of 25.00. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Kiniksa Pharmaceuticals International's value of 79.30% is 791% above this industry median. Based on the distribution chart, Kiniksa Pharmaceuticals International ranks #35 out of 809 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's 3-Year EBITDA Growth Rate compare to AMRX and LQDA?
According to the Drug Manufacturers industry distribution chart, Kiniksa Pharmaceuticals International ranks #35 out of 809 companies for 3-Year EBITDA Growth Rate. This places Kiniksa Pharmaceuticals International in the top 4% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Kiniksa Pharmaceuticals International's value of 79.30% is 791% above this benchmark. While the company's 10-year median is 25.00 vs. the industry median of 8.90, Kiniksa Pharmaceuticals International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kiniksa Pharmaceuticals International's current 3-Year EBITDA Growth Rate of 79.30% is 791% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Kiniksa Pharmaceuticals International and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kiniksa Pharmaceuticals International's current 3-Year EBITDA Growth Rate is 79.30%, which is 217% above median its own 10-year median of 25.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Significantly Overvalued. The stock's GF Value™ is $55.28, compared to a current price of $79.29 — trading 43.4% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 79.30%, which is 217% above median its 10-year median of 25.00 and 791% above the Drug Manufacturers industry median of 8.90. Kiniksa Pharmaceuticals International's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current 3-Year EBITDA Growth Rate is 79.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued.
The current stock price of $79.29 is trading 43.4% above its estimated GF Value™ of $55.28.
GuruFocus considers Kiniksa Pharmaceuticals International to be Significantly Overvalued.
Key valuation signals for KNSA:
3-Year EBITDA Growth Rate: 79.30% (217% above median its 10-year median of 25.00)
GF Value™: $55.28 vs. price of $79.29 (43.4% above fair value)
Industry Position: 791% above the Drug Manufacturers median (#35 of 809)
No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
46GF Score
Get the complete analysis for KNSA
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNSA has been successfully added to your 
